Literature DB >> 2839796

Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat.

P K Mulderry1, M A Ghatei, R A Spokes, P M Jones, A M Pierson, Q A Hamid, S Kanse, S G Amara, J M Burrin, S Legon.   

Abstract

Expression of the calcitonin gene-related peptide, alpha-calcitonin gene-related peptide (CGRP), and the homologous beta-CGRP were compared in sensory and enteric nerves of the rat. Analysis of CGRP-like immunoreactivity by cation exchange chromatography and radioimmunoassay showed that in the dorsal root ganglia, dorsal spinal cord and in those peripheral tissues where CGRP-like immunoreactivity is primarily localized to sensory fibres, alpha-CGRP concentrations were three to six times greater than beta-CGRP concentrations. In the intestine, however, beta-CGRP concentrations were up to seven times greater than alpha-CGRP concentrations. Only beta-CGRP was detected in the intestines of capsaicin-treated rats. Northern blot and in situ hybridization to alpha-CGRP- and beta-CGRP-specific probes showed that while both alpha-CGRP and beta-CGRP messenger ribonucleic acids occurred in the dorsal root ganglia, only beta-CGRP messenger ribonucleic acid occurred in the intestine, where it was localized to enteric neurons. Receptor binding sites on membranes of rat heart and colon had approximately equal affinities for alpha-CGRP and beta-CGRP. The two peptides were equipotent in increasing the rate and force of atrial contractions but alpha-CGRP was slightly (2.6 times) more potent than beta-CGRP in relaxing colonic smooth muscle. Thus, both alpha-CGRP and beta-CGRP occur in the rat nervous system and are both biologically active. Sensory neurons and enteric neurons have been identified as populations which preferentially express alpha-CGRP and beta-CGRP, respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839796     DOI: 10.1016/0306-4522(88)90018-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  80 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Calcitonin gene related peptide.

Authors:  D J O'Halloran; S R Bloom
Journal:  BMJ       Date:  1991-03-30

Review 3.  Sensory neuron regulation of gastrointestinal inflammation and bacterial host defence.

Authors:  N Y Lai; K Mills; I M Chiu
Journal:  J Intern Med       Date:  2017-02-02       Impact factor: 8.989

Review 4.  Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine.

Authors:  Paul L Durham
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

5.  An immunohistochemical study of the innervation of the large intestine of the toad (Bufo marinus).

Authors:  S Murphy; G Campbell
Journal:  Cell Tissue Res       Date:  1993-10       Impact factor: 5.249

6.  The effects of capsaicin upon electrogenic ion transport in rat descending colon.

Authors:  S Yarrow; J A Ferrar; H M Cox
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

Review 7.  Botulinum toxin for the treatment of musculoskeletal pain and spasm.

Authors:  Geoffrey Sheean
Journal:  Curr Pain Headache Rep       Date:  2002-12

8.  Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn's disease rat model.

Authors:  Toru Kono; Yuji Omiya; Yoshiki Hira; Atsushi Kaneko; Shinichi Chiba; Tatsuya Suzuki; Masamichi Noguchi; Tsuyoshi Watanabe
Journal:  J Gastroenterol       Date:  2011-08-02       Impact factor: 7.527

Review 9.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

10.  Vesico-inhibitory responses and capsaicin-sensitive afferents in rats.

Authors:  B Conte; C A Maggi; A Meli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.